全文获取类型
收费全文 | 72995篇 |
免费 | 7143篇 |
国内免费 | 2384篇 |
专业分类
耳鼻咽喉 | 398篇 |
儿科学 | 755篇 |
妇产科学 | 470篇 |
基础医学 | 3144篇 |
口腔科学 | 4361篇 |
临床医学 | 6042篇 |
内科学 | 7636篇 |
皮肤病学 | 1162篇 |
神经病学 | 2208篇 |
特种医学 | 785篇 |
外国民族医学 | 7篇 |
外科学 | 2284篇 |
综合类 | 9172篇 |
现状与发展 | 5篇 |
一般理论 | 3篇 |
预防医学 | 4702篇 |
眼科学 | 645篇 |
药学 | 30625篇 |
32篇 | |
中国医学 | 3678篇 |
肿瘤学 | 4408篇 |
出版年
2024年 | 103篇 |
2023年 | 1256篇 |
2022年 | 1574篇 |
2021年 | 2567篇 |
2020年 | 2712篇 |
2019年 | 2960篇 |
2018年 | 3061篇 |
2017年 | 2998篇 |
2016年 | 2818篇 |
2015年 | 2763篇 |
2014年 | 4947篇 |
2013年 | 7618篇 |
2012年 | 4826篇 |
2011年 | 5096篇 |
2010年 | 3937篇 |
2009年 | 3602篇 |
2008年 | 3364篇 |
2007年 | 3388篇 |
2006年 | 2970篇 |
2005年 | 2686篇 |
2004年 | 2273篇 |
2003年 | 2077篇 |
2002年 | 1559篇 |
2001年 | 1528篇 |
2000年 | 1150篇 |
1999年 | 995篇 |
1998年 | 857篇 |
1997年 | 772篇 |
1996年 | 662篇 |
1995年 | 635篇 |
1994年 | 540篇 |
1993年 | 438篇 |
1992年 | 516篇 |
1991年 | 413篇 |
1990年 | 343篇 |
1989年 | 275篇 |
1988年 | 274篇 |
1987年 | 261篇 |
1986年 | 203篇 |
1985年 | 304篇 |
1984年 | 227篇 |
1983年 | 170篇 |
1982年 | 153篇 |
1981年 | 114篇 |
1980年 | 79篇 |
1979年 | 76篇 |
1978年 | 85篇 |
1977年 | 58篇 |
1976年 | 59篇 |
1975年 | 62篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
41.
42.
43.
《Journal of the American College of Radiology》2022,19(5):655-662
PurposeTo improve the efficiency and accuracy of clinicians documenting acute clinical events related to contrast agent administration using a web browser–based semistructured documentation support tool.MethodsA new tool called Contrast Incident Support and Reporting (CISaR) was developed to enable radiologists responding to contrast reactions to document inciting contrast class, type of event, severity of contrast reaction, and recommendation for future contrast use. Retrospective analysis was conducted of all CT and MRI examinations performed between February 2018 and December 2019 across our hospital system with associated contrast reaction documentation. Time periods were defined as before tool deployment, early adoption, and steady-state deployment. The primary outcome measure was the presence of event documentation by a radiologist. The secondary outcome measure was completeness of the documentation parameters.ResultsA total of 431 CT and MRI studies with reactions were included in the study, and 50% of studies had radiologist documentation during the pre-CISaR period. This increased to 66% during the early adoption period and 89% in the post-CISaR period. It took approximately 9 months from the introduction of CISaR to reach full adoption and become the main method for adverse contrast reaction documentation. The percentage of radiologist documentation that detailed provoking contrast agent class, severity of reaction, reaction type, and future contrast agent recommendation all significantly increased (P < .0001), with greater than 95% inclusion of each element.ConclusionThe implementation of a semistructured electronic application for adverse contrast reaction reporting significantly increased radiologist documentation rate and completeness of the documentation. 相似文献
44.
《Research in social & administrative pharmacy》2022,18(8):3284-3289
BackgroundAdverse drug reactions (ADRs) and adverse drug events (ADEs) in older people contribute to a significant proportion of hospital admissions and are common following discharge. Effective interventions are therefore required to combat the growing burden of preventable ADRs. The Prediction of Hospitalisation due to Adverse Drug Reactions in Elderly Community Dwelling Patients (PADR-EC) score is a validated risk score developed to assess the risk of ADRs in people aged 65 years and older and has the potential to be utilised as part of an intervention to reduce ADRs.ObjectivesThis trial was designed to investigate the effectiveness of an intervention to reduce ADR incidence in older people and to obtain further information about ADRs and ADEs in the 12–24 months following hospital discharge.MethodsThe study is an open-label randomised-controlled trial to be conducted at the Royal Hobart Hospital, a 500-bed public hospital in Tasmania, Australia. Community-dwelling patients aged 65 years and older with an unplanned overnight admission to a general medical ward will be recruited. Following admission, the PADR-EC ADR score will be calculated by a research pharmacist, with the risk communicated to clinicians and discussed with participants. Following discharge, nominated general practitioners and community pharmacists will receive the risk score and related medication management advice to guide their ongoing care of the patient. Follow-up with participants will occur at 3 and 12 and 18 and 24 months to identify ADRs and ADEs. The primary outcome is moderate-severe ADRs at 12 months post-discharge, and will be analysed using the cumulative incidence proportion, survival analysis and Poisson regression.SummaryIt is hypothesised that the trial will reduce ADRs and ADEs in the intervention population. The study will also provide valuable data on post-discharge ADRs and ADEs up to 24 months post-discharge. 相似文献
45.
异质性耐药是一种特殊的细菌耐药类型,常表现为同一克隆来源的不同细菌亚群对某种抗菌药物表现出不一致的耐药特征,大多数亚群对某种抗菌药物敏感,而少部分亚群对其耐药或高度耐药。异质性耐药分离株常会导致特定抗菌药物抗感染治疗失败。针对异质性耐药菌较为深入的研究主要集中于革兰阴性菌,革兰阳性球菌的相关报道较少。近年有研究报道万古霉素、利奈唑胺、苯唑西林等多种类型抗菌药物异质性耐药金黄色葡萄球菌分离株出现,但其实际临床意义尚待进一步评估。此文对金黄色葡萄球菌异质性耐药机制和检测技术最新进展进行综述,为细菌异质性耐药机制研究和新型检测技术研发提供新的思路。 相似文献
46.
Biologics and immunomodulators (IMM) are generally considered the most effective therapies for the treatment of ulcerative colitis and Crohn’s disease. However, despite the efficacy of these therapies, many patients either have a primary lack of response or a secondary loss of response to these medications. Therapeutic drug monitoring (TDM) is a systematic approach to managing such patients. In this review, we summarize the latest data on TDM, including reactive and proactive TDM, in patients with inflammatory bowel disease on biologics and/or IMM. 相似文献
47.
48.
49.
Key Concerns Regarding Research on the Effect of Omega-3 Fortified Oral Nutrition on Nutritional Indices and Quality of Life in Patients with Gastrointestinal Cancer 下载免费PDF全文
50.
Conan MacDougall Theora Canonica Chris Keh Binh An P. Phan Janice Louie 《Pharmacotherapy》2022,42(4):343-361
Rifamycins (rifampin, rifabutin, and rifapentine) play an essential role in the treatment of mycobacterial and some nonmycobacterial infections. They also induce the activity of various drug transporting and metabolizing enzymes, which can impact the concentrations and efficacy of substrates. Many anticoagulant and antiplatelet (AC/AP) agents are substrates of these enzymes and have narrow therapeutic indices, leading to risks of thrombosis or bleeding when coadministered with rifamycins. The objective of this systematic review was to evaluate the effects on AC/AP pharmacokinetics, laboratory markers, and clinical safety and efficacy of combined use with rifamycins. A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidance was performed. The PubMed, Embase, and Web of Science databases were queried for English-language reports on combination use of rifamycins and AC/AP agents from database inception through August 2021. The 29 studies identified examined warfarin (n = 17), direct oral anticoagulants (DOACs) (n = 8), and antiplatelet agents (n = 4) combined with rifampin (n = 28) or rifabutin (n = 1). Eleven studies were case reports or small case series; 14 reported on pharmacokinetic or laboratory markers in healthy volunteers. Rifampin-warfarin combinations led to reductions in warfarin area under the curve (AUC) of 15%–74%, with variability by warfarin isomer and study. Warfarin dose increases of up to 3–5 times prerifampin doses were required to maintain coagulation parameters in the therapeutic range. DOAC AUCs were decreased by 20%–67%, with variability by individual agent and with rifampin versus rifabutin. The active metabolite of clopidogrel increased substantially with rifampin coadministration, whereas prasugrel was largely unaffected and ticagrelor saw decreases. Our review suggests most combinations of AC/AP agents and rifampin are problematic. Further studies are required to determine whether rifabutin or rifapentine could be safe alternatives for coadministration with AC/AP drugs. 相似文献